Curative intent therapy of stage I–III non-small cell lung cancer: a patient-centered precision approach to assess, measure, and interpret benefits and harms

This study has important implications in clinical decision-making and the design of future trials to prevent overtreatment or undertreatment, maximize benefits, minimize harms, and achieve net benefit over harm in beneficent care for this growing population.